source
- Yarrow goes public while Otsuka receives FDA approval for new ADHD medicationYarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the ass…
- AstraZeneca says AI has yet to yield clinical candidates but could lower risk in late-stage trialsAstraZeneca's chief executive Pascal Soriot told reporters that the company's AI‑driven efforts in drug design have not yet produced a candidate that has entered clinical testing. He added that th…